Hernexeos zongertinib

Drug Class

HER2 tyrosine kinase inhibitor

Mechanism

Selectively inhibits the kinase domain of HER2 while sparing wild-type EGFR, blocking downstream oncogenic signaling.

Approved Indication

Advanced HER2 tyrosine kinase domain-mutated non-squamous non-small cell lung cancer, per its FDA approval.

What This Means For Patients

Hernexeos is a selective oral tyrosine kinase inhibitor designed to treat advanced non-small cell lung cancer driven by HER2 mutations. By specifically targeting mutant HER2, it helps block cancer cell proliferation and is available in Hainan Lecheng.

Regulatory Approvals

• FDA — approved (2025) — source

Pivotal Clinical Evidence

• Beamion LUNG-1 — Heymach et al., N Engl J Med 2026 (NCT04886804) — DOI

Sources

• https://www.boehringer-ingelheim.com/us/press-releases/fda-approves-zongertinib-her2-mutant-nsclc
• https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=219808